Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2013

View Archived Issues

The Korea Institute of Ocean Science and Technology synthesizes novel agents for cancer

Vertex Pharmaceuticals discloses new agents for influenza

New agents that inhibit AIMP2-DX2 selected by Korean researchers

XOMA-3AB well tolerated in phase I study

Tulane University researchers describe B. pseudomallei vaccine strategy

Takeda Pharmaceutical synthesizes new inhibitors of ROR gamma t

Dainippon Sumitomo Pharma divulges new neutrophil elastase inhibitors

Pooled phase Ib results for dupilumab show efficacy in atopic dermatitis

Second phase III trial of tavaborole in onychomycosis meets endpoints

Cubist Pharmaceuticals obtains QIDP and fast track designations for late-stage antibiotic candidates

FluoroPharma Medical reports data from phase II CardioPET study

Kythera Biopharmaceuticals presents phase III results for ATX-101

Adventrx Pharmaceuticals to change name, provides update on ANX-188

BioAlliance Pharma signs agreement with global vaccine company

Progen signs licensing agreement for PG-545

Pseudomonas-specific antibiotic POL-7080 completes phase I study

Novo Nordisk launches new long-acting insulin Tresiba in Denmark

Santhera considering strategic options following decisions regarding Catena and Raxone

NeuroDerm completes phase I study of levodopa/carbidopa patch pump

Enrollment completed in phase II study of PsiOxus' MT-102 for cancer cachexia

FDA approves revised SPA for phase III trial of Collategene in critical limb ischemia

FDA approves expanded indication for Corifact

miRNAs as novel targets in androgen-independent prostate cancer

UCLA receives funding to identify genetic changes that affect the severity of DMD

Companies partner to advance allosteric modulators targeting adenosine A2A receptor

Alere receives Gates Foundation grant to develop tuberculosis assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...